Vol. 22/No. 09

Investigators are studying LN-145, a novel immunotherapy developed from autologous tumor-infiltrating lymphocytes, as a potential new option for patients with unresectable or metastatic non–small cell lung cancer after disease progression on a checkpoint inhibitor and chemotherapy.

In the United States, a geographic mismatch exists between the number of medical oncology and radiation providers and patients needing care, with more specialists clustered in urban and metropolitan areas.

Frequently dysregulated in cancer cells, the PI3K pathway has long been a high-priority therapeutic target in oncology. However, initial efforts with pan–class I PI3K inhibitors were hampered by disappointing efficacy and substantial toxicity.

Daniel J. George, MD, discussed how tivozanib differs from other TKIs and its potential to fill an unmet need in the treatment of patients with renal cell carcinoma.

The highly heterogeneous nature of cholangiocarcinoma at the genomic, epigenetic, and molecular levels has led to the development of effective new treatments for patients with these rare malignant tumors.

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.

OncologyLive® Advisory Board members speak about how COVID-19 has touched all aspects of oncology practice, research, and treatment.

Lowell L. Hart, MD, discusses trilaciclib’s unique role in patients with ES-SCLC who experience myelosuppression, as well as the future role of the agent.